Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
about
Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2DCharacterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesOptimal treatment for chronic active Epstein-Barr virus diseaseEpstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetHow we treat chronic active Epstein-Barr virus infection.High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsAdverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersClinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation.Multiple Epstein-Barr virus infections in healthy individualsTreatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremiaClinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.Natural killer-cell malignancies: diagnosis and treatment.Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scaleGenerating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?Epstein-Barr virus: silent companion or causative agent of chronic liver disease?Immune control of oncogenic γ-herpesviruses.Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia.Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.A Case Report of NK-Cell Lymphoproliferative Disease With a Wide Involvement of Digestive Tract Develop Into Epstein-Barr Virus Associated NK/T Cell Lymphoma in an Immunocompetent Patient.Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.Impact of T cell selection methods in the success of clinical adoptive immunotherapy.Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.RNA-based gene transfer for adult stem cells and T cells.Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.The clinical characteristics and the features of immunophenotype of peripheral lymphocytes of adult onset chronic active Epstein-Barr virus disease at a Tertiary Care Hospital in Beijing.Adoptive cell therapy against EBV-related malignancies: a survey of clinical resultsSpleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated LymphomaHematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders
P2860
Q24616577-DC430202-65C9-479F-9A44-3F089B62F2A3Q24617384-8A7A8211-37BF-4BA2-9C8F-CF690DD34394Q24657703-35F2BDE3-AC6A-4BA3-AE12-275120953317Q26822550-2AA9BD35-25F7-4AD6-B1CE-F911560618BAQ30235902-39E55A57-A27B-4326-B862-607DF3B50FE6Q33806895-A9DE874D-F2F1-4178-915D-4EDFE7142912Q34039992-A66BB135-5B8A-4FB5-9158-26D0E82BEA4AQ34166602-26B43D79-69F0-4B60-BD2E-30E50FFEAA3DQ34770812-DAA7437F-B9B0-47BB-BDA4-F49863BAD6D3Q34997005-6D1DA701-8892-47B2-8088-0FEE5D78E2F3Q35686137-3A8D2124-176B-4EB1-960B-B50DD5D79BE5Q35803089-779B820A-A679-4DAF-9E68-41533351B01EQ35809452-50C147D9-C2E6-4B74-B60E-7DC656AE5EFCQ35849039-824748BD-80C1-4D9A-8A83-2EA055ACC0ABQ36059585-E107CB3E-7389-4E0D-A8F8-1060E707CD61Q36265596-71026744-9D97-41E3-8C36-1D94EA93DD7EQ36475411-E63E3E92-0F04-4244-96DC-44733D03DE14Q36558219-B5F3E911-74E0-4B61-BE44-F4C41D9DF34CQ37257276-889DE344-96D1-4B91-9D36-85DE57328DDCQ37549726-BBF17B77-3070-4848-A174-8A2956F273E1Q37563023-07687EA7-629B-4FD3-8488-9001FE16C238Q37784165-F6A45C58-F9D0-4D47-B1AE-3175AAC80CA7Q38587362-70C112D5-C635-4FE7-BE08-CF75945C17E0Q39506626-68D10090-389A-432D-9CA1-BA01565E699DQ39966752-E6DAA7AD-9D6B-4328-8195-21D81F37FB08Q40080577-AD485365-8177-4BE5-9A43-06933607EE11Q40303777-E52CDAA9-3B2C-4C20-A761-7886D1FA3F41Q40457809-E9C2B33C-D9F9-4DA1-A4F0-EED4AFC3D23EQ40740726-23D7E9AA-8FC3-4B04-B452-C790B6A1ABA6Q42229199-F760D196-36C6-4732-8440-587F89A04D94Q42265908-AC6B848A-030F-404F-B9AC-08C8C22C29D0Q42955165-0C40F525-BED0-41D4-BA65-C970C60660EEQ43065304-52B3FB0C-5FA1-41F3-9A4F-D465095F7841Q45248732-144D6C1A-E2CD-430E-973D-22BEFA93637FQ45414813-724BE7B7-F30A-4FA3-B145-3DEE3A173A33Q54264987-6A27D076-C9AC-4B1D-8CC7-808A589643B7Q57056125-B6D6C99A-0329-4CD7-B385-E7B27E3872F9Q58721423-E9B148AD-3A0E-4903-B5FE-A4E42A0802E5Q59128393-907EE6B1-DE81-4D0D-BAE7-C91D7BDBEF70
P2860
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Autologous Epstein-Barr virus ...... rsistent active EBV infection.
@en
type
label
Autologous Epstein-Barr virus ...... rsistent active EBV infection.
@en
prefLabel
Autologous Epstein-Barr virus ...... rsistent active EBV infection.
@en
P2093
P1433
P1476
Autologous Epstein-Barr virus ...... rsistent active EBV infection.
@en
P2093
Adrian P Gee
Barbara Savoldo
Cliona M Rooney
Hans-Dieter Volk
Helen E Heslop
James F Jones
Jennifer Webster-Cyriaque
M Helen Huls
Malcolm K Brenner
Nina Babel
P304
P356
10.1182/BLOOD-2002-01-0039
P407
P50
P577
2002-08-01T00:00:00Z